Juan Antonio Castillo

Atherogenic responsibility of lipoprotein (a) and other apolipoprotein B-containing lipoproteins in #ACS- Atherosclerosis atherosclerosis-journal.com/article/S0021-…

Cerramos nuestra participación en #SEC25 con la comunicación "Importancia de colesterol HDL y lipoproteina (a) en el perfil de riesgo cardiovascular del paciente con síndrome coronario agudo recurrente", que presenta @franbuendia97 @J_M_Andreu @ameseguer97 @PatonRubio @SMurCardio

Otra gran jornada de los resis de Cardio del H Stª Lucía @Area2Cartagena en el Congreso #SEC25 a los que se ha sumado nuestra excelente enfermera de IC @ameseguer97 @franbuendia97 @J_M_Andreu @SMurCardio @sedes_jose @PatonRubio @Doctorabellan @secardiologia

¡Que bien han defendido los resis de Cardio del Hospital Stª Lucía @Area2Cartagena sus comunicaciones orales durante la primera joranada de #SEC25 ! Mañana más... @franbuendia97 @J_M_Andreu @SMurCardio @Doctorabellan @PatonRubio @secardiologia

Atherosclerosis publishes our study (Cardiology & Clinical Lab, Hospital St. Lucía @Area2Cartagena @franbuendia97 @J_M_Andreu @ameseguer97 @Cardiogarcia @Doctorabellan @_rMarmol_ @DrDau3 @SMurCardio @secardiologia

ATHEROGENIC RESPONSIBILITY OF LIPOPROTEIN (a) AND OTHER APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS IN ACUTE CORONARY SYNDROME. - Atherosclerosis atherosclerosis-journal.com/article/S0021-…

Atherosclerosis publishes our study (Cardiology & Clinical Lab, Hospital St. Lucía @area2Cartagena) "Atherogenic responsibility of lipoprotein (a) and other apolipoprotein B-containing lipoproteins in acute coronary syndrome" @franbuendia97 @J_M_Andreu @ameseguer97 @SMurCardio

.@ameseguer97: El estudio AQUATIC, primer ensayo aleatorizado y doble ciego en este campo, aclara la duda existente en el balance entre el riesgo hemorrágico y aterotrombótico: menos es más". #BlogSEC @jovenesSEC ow.ly/LqXV50X00UB

The AQUATIC trial may be the most definitive trial of #ESCCOngress The common combo of ASA and OAC for pts with CAD/stent and AF is clearly been harming people. Lots. MACE worse, Death worse, Bleeding way worse. STOP THE ASA when on OAC nejm.org/doi/full/10.10…

Presenting at #ESCCongress: Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials hubs.li/Q03GhXVv0

Presenting at #ESCCongress: Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial hubs.li/Q03GhX-80

Presented at #ESCCongress: Among patients with myocardial infarction and a left ventricular ejection fraction of more than 40%, beta-blockers did not lead to a lower incidence of death, reinfarction, or hospitalization for heart failure than no beta-blocker therapy. Full REBOOT trial results: nej.md/45QYbws @escardio

Presented at #ESCCongress: Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results: nej.md/4oT6aSg @escardio

Original Article: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias (POTCAST trial) nej.md/4oQtHTN #ESCCongress | @escardio

Presented at #ESCCongress: In patients with STEMI with cardiogenic shock, early mechanical support with a microaxial pump reduced the risk of death at 180 days, with the survival benefit persisting up to 10 years despite device-related complications. Full DanGer Shock trial results: nej.md/47JkdDE @escardio

Original Article: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC trial) nej.md/45AU4Wp #ESCCongress | @escardio

Original Article: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET trial) nej.md/3VeTJT8 #ESCCongress | @escardio

Original Article: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction (TARGET-FIRST trial) nej.md/3UKJxS7 #ESCCongress | @escardio

Original Article: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome (TACSI trial) nej.md/45OjEWN #ESCCongress | @escardio

Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results and Research Summary: nej.md/4oT6aSg